AlphAIalphai — Financial news for AI agents
aol.comAUG 193 min read$ACH

Accendra Health (ACH) Q2 2026 Earnings Call Transcript

Accendra Health (ACH) reported Q2 2026 revenue of $613.2M, down from $681.9M YoY, and adjusted EBITDA of $60.1M, down from $96.6M. The company revised full-year revenue guidance to $2.45B-$2.55B and adjusted EBITDA to $300M-$320M, citing slower growth and collection rate issues. Total debt decreased by $385M to $1.72B. CEO Edward Pesicka announced his retirement by year-end.

Original reporting
aol.com
Published Aug 19, 2026, 7:25 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 1:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Accendra Health (ACH) Q2 2026 Earnings Call Transcript — source image
Source · aol.com
Decision brief

The 30-second read

$ACHBearishHigh
01

Why it matters

The revised guidance suggests lower near-term earnings, but strategic initiatives may mitigate long-term risk.

02

Market read

Earnings miss and guidance downgrade are likely to move ACH stock, with sector peers watching collection trends.

03

What to watch

Potential upside from the new sole-source agreement launching in 2027 and the Sleep Center rollout.

Relevance 8/10Novelty 8/10Timing: pre-market

Background

Accendra Health reported Q2 results below internal expectations, revising full-year guidance amid collection headwinds.

Company-level read

Ticker impact

$ACHBearishHigh confidence
Context

Q2 2026 earnings release with revised full-year revenue and EBITDA guidance, plus debt reduction details.

Expected impact

Potential short-term decline, with volatility as investors reassess valuation.

Evidence & confidence

Revenue guidance lowered and collection issues highlighted; market may react negatively to weaker outlook.

Market effects

Sector

Home-based healthcare and medical device sectors may see broader scrutiny on payer collection trends.

Regional

U.S. healthcare stocks could face pressure amid earnings downgrades.

Global

Limited to U.S. markets; no immediate global macro impact.

Counterpoint

What could challenge this read

Cost reductions and debt paydown could support a rebound if collection issues improve.

Key entities

  • Executive
    Edward Pesicka

    CEO announcing retirement and leading transformation.

  • Executive
    Jonathan Leon

    CFO discussing debt reduction and cash interest.

Read at source← All news

Related articles

AUG 17
$ACHMedAI 8/10

Accendra Health (ACH) Q2 2026 Earnings Call Transcript

Accendra Health (ACH) reported Q2 2026 net revenue of $613.2 million, down from $681.9 million a year earlier, and adjusted EBITDA of $60.1 million versus $96.6 million. Full-year revenue guidance was revised to $2.45 billion to $2.55 billion and adjusted EBITDA to $300 million to $320 million. Debt fell to $1.72 billion as of June 30, 2026.

fool.com6 min
AUG 10
$ACHMedAI 8/10

Accendra Health Reports Lower Q2 Revenue, Sets 2026 Guidance; Adopts Tax Asset Plan; Stock Down

Accendra Health (ACH) reported Q2 2026 revenue of $613.2 million, down from $681.9 million a year earlier, with GAAP net loss of $89.1 million ($1.16/share). Non-GAAP adjusted net loss was $14.3 million. Adjusted EBITDA fell to $60.1 million and free cash flow was -$25.1 million. The company guided FY2026 revenue $2.45-$2.55 billion and adjusted EBITDA $300-$320 million, and adopted a tax asset preservation plan.

rttnews.com5 min
AUG 10
$ACHMed

ACCENDRA HEALTH INC/VA/ (ACH): Results of Operations and Financial Condition

ACCENDRA HEALTH INC/VA/ (ACH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622667d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Accendra Health Reports Second Quarter 2026 Financial Results Reduced Total Debt By $385 Million In Second Quarter CEO Ed Pesicka Announces Intention To Retire By The End of 2026 RICHMOND, VA – August 10, 2026 – Accendra

SEC EDGAR 8-K6 min
JUL 12
$ACHMed

Accendra Health (ACH) is One of The 15 Best NYSE Penny Stocks According to Hedge Funds

Accendra Health Inc. (NYSE:ACH) said on June 23 it completed exchange offers for its 4.5% senior notes due 2029 and 6.625% senior notes due 2030. The notes were exchanged for new 9% senior secured first-lien notes due 2032 and 9.75% senior secured second-lien notes due 2033. Accendra expects to issue about $539.25 million first-lien notes and about $698.1 million second-lien notes, while S&P Global Ratings affirmed a 'B' issuer rating and moved outlook to stable.

yahoo.com3 min
AUG 24
$MCKMed

Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation?

McKesson Corporation (MCK) reports double-digit earnings growth and raises fiscal 2027 guidance to $44.20-$45.00 per share. Specialty businesses show strong growth, but shares trade at a premium valuation (18.4X forward earnings) above historical and industry benchmarks. The company is repurchasing $5 billion in stock and raised its dividend by 15%.

yahoo.com3 min
AUG 24
$GEHCMed

GEHC Q2 Orders Surge 11.1% as Record Backlog Builds 2027 Visibility

GE HealthCare Technologies reported an 11.1% year-over-year increase in organic orders for Q2, with a record backlog of $23.9 billion. Orders grew across all segments, and 85% of Q3 equipment revenue is already secured. The company reaffirmed its full-year revenue growth guidance of 3% to 4%, but execution and inflation remain key challenges.

yahoo.com2 min